Genetic Polymorphism and Its Impact on Atorvastatin Efficacy: Personalizing Hyperlipidemia Treatment
Hyperlipidemia is a main risk factor for coronary heart disease, which is commonly treated with statins, especially atorvastatin. However, the efficacy and harmful effects vary from person to person. Nearly 50% discontinue treatment within one year, mainly because of intolerance to statins associated with musculoskeletal symptoms. The presence of genetic polymorphisms in various genes greatly affects atorvastatin metabolism, response, and adverse events. This review covers pharmacogenetics in genes such as APOE, HMGCR, CYP3A4, CYP3A5, CYP2D6, CETP, LDLR, PCSK9, ABCB1, ABCG5/8, SLCO1B1, and KIF6 affecting atorvastatin lipid-lowering therapeutic action. The knowledge of these genetic factors is crucial in adjusting therapy to reduce adverse reactions and in paving the way for personalized therapeutics in the management of hyperlipidemia.
-
Genetic Polymorphism, Statin, Atorvastatin, Hyperlipidemia, LDL, HDL
-
(1) Huma Sajjad
ASHP IPPRP Resident Pharmacist, Shifa International Hospital (SIH), Islamabad, Pakistan.
(2) Syed Muhammad Talha
ASHP IPPRP Resident Pharmacist, Shifa International Hospital (SIH), Islamabad, Pakistan.
(3) Syed Qurat ul Ain Ali
Staff Pharmacist, Shifa International Hospital (SIH), Islamabad, Pakistan.
(4) Hufsa Arooj
Clinical Trial Pharmacist, Pakistan Institute of Medical Sciences (PIMS), Islamabad, Pakistan.
Cite this article
-
APA : Sajjad, H., Talha, S. M., & Ali, S. Q. u. A. (2024). Genetic Polymorphism and Its Impact on Atorvastatin Efficacy: Personalizing Hyperlipidemia Treatment. Global Pharmaceutical Sciences Review, IX(I), 29-50. https://doi.org/10.31703/gpsr.2024(IX-I).03
-
CHICAGO : Sajjad, Huma, Syed Muhammad Talha, and Syed Qurat ul Ain Ali. 2024. "Genetic Polymorphism and Its Impact on Atorvastatin Efficacy: Personalizing Hyperlipidemia Treatment." Global Pharmaceutical Sciences Review, IX (I): 29-50 doi: 10.31703/gpsr.2024(IX-I).03
-
HARVARD : SAJJAD, H., TALHA, S. M. & ALI, S. Q. U. A. 2024. Genetic Polymorphism and Its Impact on Atorvastatin Efficacy: Personalizing Hyperlipidemia Treatment. Global Pharmaceutical Sciences Review, IX, 29-50.
-
MHRA : Sajjad, Huma, Syed Muhammad Talha, and Syed Qurat ul Ain Ali. 2024. "Genetic Polymorphism and Its Impact on Atorvastatin Efficacy: Personalizing Hyperlipidemia Treatment." Global Pharmaceutical Sciences Review, IX: 29-50
-
MLA : Sajjad, Huma, Syed Muhammad Talha, and Syed Qurat ul Ain Ali. "Genetic Polymorphism and Its Impact on Atorvastatin Efficacy: Personalizing Hyperlipidemia Treatment." Global Pharmaceutical Sciences Review, IX.I (2024): 29-50 Print.
-
OXFORD : Sajjad, Huma, Talha, Syed Muhammad, and Ali, Syed Qurat ul Ain (2024), "Genetic Polymorphism and Its Impact on Atorvastatin Efficacy: Personalizing Hyperlipidemia Treatment", Global Pharmaceutical Sciences Review, IX (I), 29-50
-
TURABIAN : Sajjad, Huma, Syed Muhammad Talha, and Syed Qurat ul Ain Ali. "Genetic Polymorphism and Its Impact on Atorvastatin Efficacy: Personalizing Hyperlipidemia Treatment." Global Pharmaceutical Sciences Review IX, no. I (2024): 29-50. https://doi.org/10.31703/gpsr.2024(IX-I).03